Zobrazeno 1 - 10
of 24
pro vyhledávání: '"John Pieracci"'
Autor:
Vinay Bhatt, Ryan Dickerson, Christopher Argento, John Pieracci, Meisam Bakhshayeshi, Xiaotong Fu, Xiaohui Lu, Peter Clarner, Svetlana Bergelson, George M. Bou-Assaf, Wei-Chiang Chen
Publikováno v:
Human Gene Therapy Methods. 30:144-152
Recombinant adeno-associated virus (rAAV)-mediated gene therapy is a fast-evolving field in the biotechnology industry. One of the major challenges in developing a purification process for AAV gene therapy is establishing an effective yet scalable me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371c8e875f01b80c96012c68505767e2
https://doi.org/10.1089/hgtb.2019.088
https://doi.org/10.1089/hgtb.2019.088
Publikováno v:
Biotechnology journal. 16(1)
The development of recombinant adeno-associated virus (rAAV) gene therapies is becoming an increasing priority in the biotherapeutic landscape. One of the challenges associated with the production of rAAV is the formation of empty AAV particles that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19b99b71dadaf5ee47dafae95c312ac
https://pubmed.ncbi.nlm.nih.gov/33002276
https://pubmed.ncbi.nlm.nih.gov/33002276
Publikováno v:
Journal of Chromatography A. 1663:462744
Recombinant adeno-associated virus (AAV) has been broadly used as a delivery tool for gene therapy applications. The development of a robust purification process is essential for delivering high purity and quality AAV products to clinic. The short cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a272e0c23404aafb353a0d1ca36868f1
https://doi.org/10.1016/j.chroma.2021.462744
https://doi.org/10.1016/j.chroma.2021.462744
Publikováno v:
Current Opinion in Biomedical Engineering. 20:100353
As gene therapy is experiencing a second wave of interest, rAAV has rapidly emerged as one of the most attractive viral transfer tools, thanks to its favorable safety profile and long-term transgene expression. The recent approval of rAAV molecules f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca8360e7efd87352aef25dd354a45e60
https://doi.org/10.1016/j.cobme.2021.100353
https://doi.org/10.1016/j.cobme.2021.100353
Autor:
Sanchayita Ghose, Lynn Conley, Alexis Henry, Douglas Cecchini, John Pieracci, Yinying Tao, Edward Koepf
Publikováno v:
Biotechnology and Bioengineering. 114:813-820
Inclusion of a detergent in protein biotherapeutic purification processes is a simple and very robust method for inactivating enveloped viruses. The detergent Triton X-100 has been used for many years and is part of the production process of several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6320a92569d3b93fb6af41144ca5564
https://doi.org/10.1002/bit.26209
https://doi.org/10.1002/bit.26209
Publikováno v:
Eng Life Sci
With cell culture titers and productivity increasing in the last few years, pressure has been placed on downstream purification to look at alternative strategies to meet the demand of biotech products with high dose requirements. Even when the upstre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf23fae077112ed40bc73929234d37fb
https://doi.org/10.1002/elsc.201600104
https://doi.org/10.1002/elsc.201600104
Once a therapeutic protein has been produced by a chosen production system, the product must be separated and recovered from the host system. Cell harvest and recovery serve this function by removing or isolating host cells so that the product can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc8e94040ff5e0a9ba35e1297009c96c
https://doi.org/10.1016/b978-0-08-100623-8.00009-8
https://doi.org/10.1016/b978-0-08-100623-8.00009-8
Publikováno v:
Continuous Biomanufacturing-Innovative Technologies and Methods ISBN: 9783527699902
Continuous Biomanufacturing - Innovative Technologies and Methods
Continuous Biomanufacturing - Innovative Technologies and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a64f9083b424a4c1e8de0ee3b0760acf
https://doi.org/10.1002/9783527699902.ch21
https://doi.org/10.1002/9783527699902.ch21
Publikováno v:
Biotechnology progress. 34(2)
Decoupling upstream and downstream operations in biopharmaceutical production could enable more flexible manufacturing operations and could allow companies to leverage strategic or financial benefits that would be otherwise unattainable. A decoupling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609dd5768f5524c9efb41ae4e57c18ef
https://pubmed.ncbi.nlm.nih.gov/29314774
https://pubmed.ncbi.nlm.nih.gov/29314774
Publikováno v:
Biotechnology progress. 33(6)
The Biogen upstream platform is capable of delivering equivalent quality material throughout the cell line generation process. This allows us to rapidly deliver high-quality biopharmaceuticals to patients with unmet medical needs. The drive to reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b780e5057c36e0400c0e3e15aba027f4
https://pubmed.ncbi.nlm.nih.gov/28842948
https://pubmed.ncbi.nlm.nih.gov/28842948